GENFIT's NIS4 blood-based biomarker panel, commercialized as NASHnext and co-developed with Labcorp, is now accessible to consumers directly through Labcorp OnDemand — a shift that places a clinically validated, non-invasive metabolic dysfunction-associated steatohepatitis (MASH) screening tool outside the traditional physician referral pathway for the first time.
NIS4 is an algorithmic composite of four circulating biomarkers — miR-34a-5p, alpha-2-macroglobulin, YKL-40, and HbA1c — designed to identify patients with at-risk MASH without requiring liver biopsy. In published validation studies, the panel demonstrated statistically significant discrimination of at-risk MASH against histological endpoints, offering a non-invasive alternative to the current diagnostic gold standard. The test does not carry a structure-function claim and is positioned as a laboratory diagnostic, not a dietary supplement.
For operators in the functional foods and liver-health nutraceutical space, the Labcorp OnDemand listing carries meaningful downstream implications. Consumers who self-identify as at-risk through NASHnext represent a high-intent segment already engaged with metabolic health — precisely the audience driving demand for finished formulations featuring milk thistle standardized extract, TUDCA, berberine HCl, and phosphatidylcholine. The global liver health supplement market has expanded steadily alongside rising MASH prevalence, and direct-to-consumer diagnostics have historically served as a category accelerant by converting passive health interest into active purchasing behavior.
The OnDemand channel — which allows consumers to order laboratory tests without a prior physician order in eligible U.S. states — broadens access considerably compared to a specialist-gated rollout. Labcorp's national footprint of patient service centers means NASHnext is now effectively a retail-adjacent diagnostic, sitting in the same consumer decision funnel as at-home metabolic panels and CGM subscriptions. Brands and co-manufacturers targeting the NAFLD/MASH-aware consumer should note that a verified at-risk result may significantly shorten the path to supplement trial and repeat purchase.
For nutraceutical formulators and white-label partners, the practical takeaway is segmentation intelligence: as NASHnext adoption grows, expect registered dietitians, functional medicine practitioners, and direct-to-consumer wellness platforms to integrate the panel into liver-health protocols that pair diagnostic confirmation with evidence-backed supplementation. Companies with peer-reviewed clinical data on their liver-support ingredients — and clear, compliant structure-function claims on file — will be best positioned to capture that referral-adjacent demand as it materializes. Coverage of emerging metabolic health ingredients and liver-support formulation trends on Functional News provides additional context for operators building in this space.
This launch is part of a broader industry pattern tracked by the Food & Beverage Magazine network, in which clinical diagnostics and nutraceutical categories increasingly share consumer audiences and distribution infrastructure.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.